ReviewJournal of hepatocellular carcinoma2021

A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.

Angelo Dipasquale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.